Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
May 4, 2020
The Center for Biosimilars
On May 4, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).
Click to access part 1, part 2, and part 3 of the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
SCCE 14th Annual European Compliance & Ethics Institute
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Axinn Antitrust Insight: "New" HSR Form Remains in Effect For Now – Fifth Circuit Temporarily Freezes District Court Order that Vacated the New HSR Rule
Axinn Viewpoints
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
Chambers Recognizes Axinn’s Antitrust Practice in 2026 Global Rankings — With New Recognition in Cartel Category
Awards & Recognitions
Antitrust
